Kephera Diagnostics

Executive Summary

Kephera Diagnostics, a privately held US diagnostics company founded in 2016, specializes in developing and commercializing rapid immunoassay tests for infectious diseases and women's health, with a focus on parasitic infections and endometriosis. Operating a CLIA-certified, CAP-accredited laboratory in Framingham, Massachusetts, the company offers both proprietary testing services and in-development point-of-care assays. Kephera addresses significant unmet needs in underserved areas such as Chagas disease and endometriosis, where current diagnostic options are limited. With a lean operational model and a clear niche focus, the company is positioned to capture market share in the infectious disease and women's health diagnostics segments, though it faces competition from larger established players. The absence of disclosed funding rounds or valuation data suggests a bootstrapped or early-stage profile, which limits near-term scalability but may offer attractive entry for strategic partners.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for Endometriosis rapid test65% success
• Q3 2026Partnership with global health organization for Chagas test distribution70% success
• Q1 2026Series A funding round announcement50% success